This observational study will evaluate patients' perception of treatment with erythropoiesis-stimulating agents in patients with chronic kidney disease not on dialysis. Eligible patients initiated on treatment with Mircera (methoxy polyethylene glycol-epoetin beta) will be followed for 6 months.
Study Type
OBSERVATIONAL
Enrollment
815
Relative importance for patients of different attributes of ESA treatment, assessed by Choice Based Conjoint questionnaire at baseline and Month 6
Time frame: 6 months
Biological parameters: hemoglobin concentration at each observation time point.
Time frame: 6 months
Adherence to Mircera treatment assessed by a questionnaire adapted from the Morisky scale at baseline and at Month 6
Time frame: 6 months
Dose/schedule of Mircera treatment at each observation timepoint
Time frame: 6 months
Concomitant medication/treatments in the management of anemia
Time frame: 6 months
Proportion of patients with a hemoglobin level between 10 and 12 g/dL after 6 months of treatment with Mircera
Time frame: Month 6
Change in hemoglobin level
Time frame: from baseline to Month 6
Safety: Incidence of adverse events
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Aix-en-Provence, France
Unnamed facility
Ajaccio, France
Unnamed facility
Annonay, France
Unnamed facility
Arras, France
Unnamed facility
Avignon, France
Unnamed facility
Bagnols-sur-Cèze, France
Unnamed facility
Bayonne, France
Unnamed facility
Beauvais, France
Unnamed facility
Belley, France
Unnamed facility
Besançon, France
...and 99 more locations